Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and cyclin d1

lapatinib has been researched along with cyclin d1 in 4 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(cyclin d1)		Trials
(cyclin d1)		Recent Studies (post-2010) (cyclin d1)
1,9193051,44210,885705,157

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brown, PH; Gilmer, TM; Hill, JL; Hilsenbeck, SG; Kim, HT; Li, Y; Osborne, CK; Sexton, KR; Shen, Q; Strecker, TE; Wang, C; Zhang, Y1
Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W1
Aderhold, C; Erben, P; Faber, A; Hoermann, K; Hofheinz, RD; Schultz, JD; Umbreit, C; Weiss, C; Wenzel, A1
Kakudo, K; Nozaki, M; Ohnishi, Y; Yasui, H1

Other Studies

4 other study(ies) available for lapatinib and cyclin d1

ArticleYear
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
    Journal of the National Cancer Institute, 2009, Jan-21, Volume: 101, Issue:2

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclin D1; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Precancerous Conditions; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; RNA, Messenger; Signal Transduction

2009
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin D1; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome

2012
MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.
    Anticancer research, 2015, Volume: 35, Issue:7

    Topics: Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Epigenesis, Genetic; ErbB Receptors; Gefitinib; Human papillomavirus 16; Humans; Lapatinib; Matrix Metalloproteinase 9; Quinazolines; Vimentin

2015
Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
    Oncology reports, 2016, Volume: 36, Issue:5

    Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Cyclin D2; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Mouth Neoplasms; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3

2016